The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Phase I/II study of LYL314, a novel CD19/CD20-targeting CAR T-cell, for R/R LBCL
Akil Merchant, MD, Cedars-Sinai Medical Center, Los Angeles, CA, shares insights into a Phase I/II trial exploring LYL314, a CD19/CD20-targeting CAR T-cell, for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). An overall response rate of 88% and a complete response rate of 72% were demonstrated in the third-line setting. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so there was a really exciting session here in Lugano where we looked at sort of the next generation of CAR T-cell therapies. CAR T-cells, we know the ones that are approved for lymphoma, target CD19. And the next generation of CAR T-cells are dual targeting, that target both CD19 and CD20. So I presented the Phase I/II data from LYL314, which is a CD19 CD20 targeting CAR T-cell. The unique part of this CAR is that the T-cells are selected for CD62L prior to manufacturing and this selects for naive and stem-like cells which has been associated with better outcomes...
Yeah, so there was a really exciting session here in Lugano where we looked at sort of the next generation of CAR T-cell therapies. CAR T-cells, we know the ones that are approved for lymphoma, target CD19. And the next generation of CAR T-cells are dual targeting, that target both CD19 and CD20. So I presented the Phase I/II data from LYL314, which is a CD19 CD20 targeting CAR T-cell. The unique part of this CAR is that the T-cells are selected for CD62L prior to manufacturing and this selects for naive and stem-like cells which has been associated with better outcomes. So just to summarize at a high level, we saw very nice response rates and overall response rates of 88% and complete response rates of 72% in the third line setting and that trial has now been given the green light to be seamlessly rolled into a pivotal trial in the third line. We also presented some very early data on second line which showed again very promising response rates in the second line as well and the company has announced that there’s going to be a head-to-head trial in the second line coming in the future as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video
Read more...
Disclosures
Consulting: Lyell; BMS; Genmab; AbbVie
